Chemistry:TACT833

From HandWiki

TACT833 is a monoamine transporter modulator and serotonin 5-HT1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder.[1][2][3][4] It is being developed by Tactogen.[1][2][3][4] As of the first quarter of 2025, the drug is in the preclinical research stage of development.[1][2][3] The exact chemical structure of TACT833 does not yet appear to have been disclosed,[4] but it may be a benzofuran like 5-MAPB, 6-MAPB, BK-5-MAPB, or BK-6-MAPB.[5]

See also

References

  1. ↑ 1.0 1.1 1.2 "Delving into the Latest Updates on TACT411/833 with Synapse". 14 June 2025. https://synapse.patsnap.com/drug/2f1ca31c2a5e4b7d986c3d1278cb825c. 
  2. ↑ 2.0 2.1 2.2 "Psychedelics Drug Development Tracker". 2024. https://psychedelicalpha.com/data/psychedelic-drug-development-tracker. 
  3. ↑ 3.0 3.1 3.2 "Tactogen Inc – Pipeline". https://tactogen.com/pipeline/. "OUR PIPELINE: [...] COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Alcohol Use Disorder. Prevalence: 13.9%. STATUS: Preclinical. COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Anorexia / Binge Eating Disorder. Prevalence: 3.6%. STATUS: Preclinical. [...] *We will make a final decision among our lead candidates after completing IND-enabling studies. Alternate lead candidates include TACT 523." 
  4. ↑ 4.0 4.1 4.2 Matthew Baggott, Tactogen (14 November 2025). "Progress in Novel Entactogens as Therapeutics". 5th Annual Conference on Psychedelics and Psychedelic Medicine, Virtual, November 14-15, 2025. Massachusetts General Hospital. https://mghcme.org/courses/virtual-5th-annual-conference-on-psychedelics-and-psychedelic-medicine/. Retrieved 25 November 2025. 
  5. ↑ Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", US patent 20230150963, published 2023 May 18, assigned to Tactogen



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:TACT833&oldid=4309822"